Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Ascada Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,534,781

97 payments

Through program year 2024, Ascada Research LLC is reported as receiving $1,534,781 in research payments, across 97 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $89,515 26
2023 Research $199,649 18
2022 Research $52,620 1
2021 Research $1,192,997 52

Breakdown

Who paid Research payments · program years 2021–2024
  1. Gilead Sciences, Inc. $1,143,418 22 payments
  2. Moderna TX, Inc. $289,164 44 payments
  3. Novartis Pharmaceuticals Corporation $52,620 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $34,190 1 payment
  5. Boehringer Ingelheim Canada Ltd.Ltee $15,389 29 payments
Studies the money was for Research payments · program years 2021–2024
  1. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $651,510 1 payment
  2. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $289,097 43 payments
  3. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $246,716 1 payment
  4. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $75,900 1 payment
  5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $52,620 1 payment
  6. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $47,696 1 payment
  7. BI 767551 EX14870 Ph II III SARS COV 2 Ambulato $34,190 1 payment
  8. BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV $15,389 29 payments
  9. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $13,107 1 payment
  10. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $7,569 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record